Overview

Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis

Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety and efficacy of different dose regimens of ILV-094 compared with placebo, administered subcutaneously to subjects with active rheumatoid arthritis who are taking methotrexate.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Fezakinumab
Methotrexate